The Fort Worth Press - RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

USD -
AED 3.6725
AFN 63.501203
ALL 81.529489
AMD 375.111005
ANG 1.789884
AOA 917.999598
ARS 1378.494198
AUD 1.398122
AWG 1.8
AZN 1.696752
BAM 1.670018
BBD 2.021074
BDT 123.120931
BGN 1.668102
BHD 0.377344
BIF 2983.85754
BMD 1
BND 1.277223
BOB 6.933593
BRL 4.967697
BSD 1.003407
BTN 94.06767
BWP 13.491474
BYN 2.823304
BYR 19600
BZD 2.018171
CAD 1.36708
CDF 2310.999939
CHF 0.784635
CLF 0.022619
CLP 890.229776
CNY 6.824798
CNH 6.831475
COP 3571.47
CRC 457.171157
CUC 1
CUP 26.5
CVE 94.15346
CZK 20.80795
DJF 178.685179
DKK 6.38298
DOP 60.386896
DZD 132.50473
EGP 52.009303
ERN 15
ETB 157.950756
EUR 0.85413
FJD 2.217904
FKP 0.740532
GBP 0.741065
GEL 2.690259
GGP 0.740532
GHS 11.10817
GIP 0.740532
GMD 72.999808
GNF 8806.991628
GTQ 7.669581
GYD 209.952866
HKD 7.832095
HNL 26.659209
HRK 6.4378
HTG 131.351211
HUF 311.779728
IDR 17296
ILS 3.009035
IMP 0.740532
INR 94.082497
IQD 1314.468201
IRR 1319499.999977
ISK 122.81983
JEP 0.740532
JMD 158.959624
JOD 0.708958
JPY 159.630047
KES 129.211231
KGS 87.4274
KHR 4016.616359
KMF 421.000179
KPW 899.95002
KRW 1480.370022
KWD 0.30802
KYD 0.836208
KZT 464.965162
LAK 22138.636519
LBP 89858.937248
LKR 318.857162
LRD 184.634433
LSL 16.494808
LTL 2.95274
LVL 0.60489
LYD 6.345262
MAD 9.265398
MDL 17.188821
MGA 4161.845762
MKD 52.659459
MMK 2099.761028
MNT 3579.096956
MOP 8.094644
MRU 40.057552
MUR 46.740161
MVR 15.450258
MWK 1739.624204
MXN 17.352799
MYR 3.965999
MZN 63.910071
NAD 16.494808
NGN 1351.029947
NIO 36.930302
NOK 9.288545
NPR 150.509557
NZD 1.698235
OMR 0.384497
PAB 1.003488
PEN 3.448364
PGK 4.413987
PHP 60.4295
PKR 279.73666
PLN 3.62531
PYG 6311.960448
QAR 3.658464
RON 4.349896
RSD 100.23301
RUB 75.095532
RWF 1466.294941
SAR 3.750603
SBD 8.048395
SCR 13.712099
SDG 600.466171
SEK 9.219065
SGD 1.276105
SHP 0.746601
SLE 24.650078
SLL 20969.496166
SOS 573.470581
SRD 37.457977
STD 20697.981008
STN 20.921395
SVC 8.780484
SYP 110.632441
SZL 16.48863
THB 32.37699
TJS 9.447326
TMT 3.505
TND 2.91772
TOP 2.40776
TRY 44.925335
TTD 6.80289
TWD 31.552503
TZS 2600.000509
UAH 44.026505
UGX 3717.808593
UYU 39.893265
UZS 12170.349023
VES 482.15515
VND 26327.5
VUV 118.032476
WST 2.725399
XAF 560.113225
XAG 0.013134
XAU 0.000212
XCD 2.70255
XCG 1.80844
XDR 0.696601
XOF 560.115617
XPF 101.833707
YER 238.649682
ZAR 16.51235
ZMK 9001.197601
ZMW 19.090436
ZWL 321.999592
  • RBGPF

    -4.0600

    64.94

    -6.25%

  • CMSC

    0.0300

    22.86

    +0.13%

  • GSK

    -0.1450

    55.555

    -0.26%

  • BCC

    0.6500

    82.89

    +0.78%

  • BTI

    0.8900

    57.06

    +1.56%

  • BCE

    0.1150

    23.845

    +0.48%

  • RIO

    -1.8500

    98.43

    -1.88%

  • NGG

    0.9000

    86.5

    +1.04%

  • RELX

    -0.7350

    35.535

    -2.07%

  • JRI

    -0.1200

    12.88

    -0.93%

  • AZN

    -2.1000

    192.71

    -1.09%

  • RYCEF

    0.6500

    15.75

    +4.13%

  • BP

    -0.0450

    46.325

    -0.1%

  • VOD

    0.2100

    15.52

    +1.35%

  • CMSD

    0.0600

    23.19

    +0.26%

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck
RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

RedChip Companies Congratulates Former Client Cidara Therapeutics on Its $9.2 Billion Acquisition by Merck

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion.

Text size:

RedChip began introducing Cidara to its global microcap and small-cap investor network in 2021, when the company's market capitalization was under $100 million and its groundbreaking antiviral and antifungal programs were still largely undiscovered by the broader investment community.

"Cidara's journey from a sub-$100 million emerging growth story to a multibillion-dollar strategic acquisition by Merck is exactly the type of transformational outcome RedChip seeks to spotlight for investors," said Dave Gentry, CEO of RedChip Companies. "We were proud to share the Cidara story at a time when its innovative Cloudbreak® platform and long-acting antiviral programs were just beginning to attract institutional attention. Seeing that early science culminate in one of the largest biotech acquisitions of the year validates both Cidara's vision and the importance of bringing promising small-cap opportunities to investors early."

As detailed in Merck's announcement, the acquisition centers on CD388, Cidara's investigational long-acting, strain-agnostic antiviral designed to prevent influenza infection in individuals at high risk of complications. CD388, now in Phase 3 development, was granted Breakthrough Therapy Designation by the FDA and is viewed as a potentially first-in-class seasonal prevention solution with global commercial potential.

"Cidara exemplifies the type of emerging blue-chip story that aligns with RedChip's 33-year mission," Gentry added. "We congratulate the Cidara team on this extraordinary milestone and look forward to continuing our work discovering tomorrow's leading innovators today."

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 33 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

S.Jones--TFWP